A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if giving Aprepitant 4 hours before and for two days after ERCP decreases the risk of developing pancreatitis after ERCP.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Aprepitant; Fosaprepitant

Criteria

Inclusion Criteria: Patients selected for the study will be those undergoing ERCP who are at high risk for development of post-ERCP pancreatitis

• patients expected to undergo a sphincterotomy

• patients with suspected sphincter of oddi dysfunction

• patients with a known history in the past of post-ERCP pancreatitis

• patients less than 60 years of age

Exclusion Criteria:

• active pancreatitis

• if they are pregnant

• known adverse reaction to aprepitant